|
11 Mar 2020 |
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) + Yervoy® (ipilimumab) for Patients with Hepatocellular Carcinoma (HCC) Previously Treated with Sorafenib
|
|
11 Mar 2020 |
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for JNJ-6372 for the Treatment of Non-Small Cell Lung Cancer
|
|
10 Mar 2020 |
Santen and TRACON Discontinue Development of DE-122 for Wet Age-Related Macular Degeneration
|
|
10 Mar 2020 |
First Patient Dosed in IPH5201 Phase I Clinical Trial in Advanced Solid Tumors
|
|
10 Mar 2020 |
Acceleron Announces Topline Results from the Phase 2 Trial of ACE-083 in Patients with Charcot-Marie-Tooth Disease
|
|
09 Mar 2020 |
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review
|
|
09 Mar 2020 |
Bristol Myers Squibb Reports Primary Results of ELOQUENT-1 Study Evaluating Empliciti (elotuzumab) Plus Revlimid (lenalidomide) and Dexamethasone in Patients with Newly Diagnosed, Untreated Multiple Myeloma
|
|
09 Mar 2020 |
New report with sales data for recombinant therapeutic antibodies and proteins shows continued success of innovative antibodies
|
|
09 Mar 2020 |
CytoDyn Files IND and Protocol for Phase 2 Clinical Trial for Treatment of Patients with Coronavirus with Leronlimab (PRO 140)
|
|
08 Mar 2020 |
Update on Phase III DANUBE trial for Imfinzi and tremelimumab in unresectable, Stage IV bladder cancer
|
|
04 Mar 2020 |
Amunix Raises $73 Million in Series A Financing Led by Omega Funds
|
|
04 Mar 2020 |
Takeda Initiates Development of a Plasma-Derived Therapy for COVID-19
|
|
03 Mar 2020 |
FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
|
|
02 Mar 2020 |
ImmunoPrecise Announces Artificial Intelligence Collaboration with EVQLV to Accelerate Vaccine and Antibody Discovery for SARS-CoV-2 Coronavirus
|
|
02 Mar 2020 |
U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis
|
|
02 Mar 2020 |
Merck’s KEYTRUDA® (pembrolizumab) Significantly Improved Progression-Free Survival Compared with Brentuximab Vedotin in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL)
|
|
02 Mar 2020 |
FDA Accepts MorphoSys' Biologics License Application (BLA) and Grants Priority Review for Tafasitamab and Lenalidomide for the Treatment of Relapsed/Refractory DLBCL
|
|
29 Feb 2020 |
Harbour BioMed Announces U.S. FDA Approval of IND for Its Next Generation anti-CTLA-4 Antibody, HBM4003, to Treat Cancer
|
|
29 Feb 2020 |
Takeda Receives Positive CHMP Opinion for Subcutaneous Formulation of Vedolizumab for use as Maintenance Therapy in Adults with Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease
|
|
27 Feb 2020 |
iTeos Therapeutics Initiates Phase 1/2 Study with Highly Innovative Anti-TIGIT Antibody in Patients with Advanced Cancers
|
|
27 Feb 2020 |
Ultragenyx and Kyowa Kirin Announce FDA Acceptance and Priority Review Designation of Supplemental Biologics License Application for Crysvita® (burosumab) for Tumor-Induced Osteomalacia (TIO)
|
|
27 Feb 2020 |
Neurimmune Announces the Initiation of a Phase 1 Study of NI006 for the Treatment of ATTR Cardiomyopathy
|
|
27 Feb 2020 |
Harbour BioMed Receives U.S. FDA IND Approval for Phase 2 Clinical Trial and Orphan Drug Designation for Anti-PD-L1 Monoclonal Antibody, HBM9167
|
|
26 Feb 2020 |
GT Biopharma Announces Dosing First Patient In GTB-3550 TriKE(TM) Phase I/II Clinical Trial
|
|
25 Feb 2020 |
WuXi Biologics and Vir Biotechnology Announce Collaboration for Global Development of Antibodies to Treat COVID-19
|
